Effects of Mass Media Coverage on Timing and Annual Receipt of Influenza Vaccination among Medicare Elderly

Department of Community and Preventive Medicine, Division of Health Policy and Outcomes Research, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 644, Rochester, NY 14642, USA.
Health Services Research (Impact Factor: 2.78). 10/2010; 45(5 Pt 1):1287-309. DOI: 10.1111/j.1475-6773.2010.01127.x
Source: PubMed


To measure the association between mass media coverage on flu-related topics and influenza vaccination, regarding timing and annual vaccination rates, among the nationally representative community-dwelling elderly.
Years 1999, 2000, and 2001 Medicare Current Beneficiary Survey.
Cross-sectional survival analyses during each of three influenza vaccination seasons between September 1999 and December 2001. The outcome variable was daily vaccine receipt. We measured daily media coverage by counting the number of television program transcripts and newspaper/wire service articles, including keywords of influenza/flu and vaccine/shot shortage/delay. All models' covariates included three types of media, vaccine supply, and regional/individual factors.
Influenza-related reports in all three media sources had a positive association with earlier vaccination timing and annual vaccination rate. Four television networks' reports had most consistent positive effects in all models, for example, shifting the mean vaccination timing earlier by 1.8-4.1 days (p<.001) or increasing the annual vaccination rate by 2.3-7.9 percentage points (p<.001). These effects tended to be greater when reported in a headline rather than in text only and if including additional keywords, for example, vaccine shortage/delay.
Timing and annual receipt of influenza vaccination appear to be influenced by media coverage, particularly by headlines and specific reports on shortage/delay.

Download full-text


Available from: Jay Bhattacharya,
  • Source
    • "E-mail: woodyc@stanford.edu elderly seeking the influenza vaccine (Yoo et al. 2010), and in an analysis of Canadian reports on genetic testing showing that media helped guide the policy agenda (Caulfield, Bubela, and Murdoch 2007). Overall, media informs and influences trust and decision making, both personal and public. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Looking through the lens of the media reveals much about how new biotechnologies are portrayed and how these reports influence public policy and opinion. The roles of patients, scientists, and the government loom large in this equation. These stakeholders tell us what is important to them and why. But little research exists comparing representations of new clinical technologies in the mainstream media across time. What has changed in newspaper accounts of new biotechnologies since the 1970s? How are the stakeholders portrayed, and what do these individuals have to say? Here, we seek to answer these questions by examining media reporting of Laetrile and stem cell transplants during the time of their clinical advent.
    AJOB Empirical Bioethics 02/2014; 5(1). DOI:10.1080/21507716.2013.785988
  • Source
    • "For example, a celebrity campaign on colon cancer screening on the U.S. NBC's Today's Show was reported to increase the colonoscopy rate by 38% during the nine months following the airing of the show [27]. Although influenza was ranked 4th among all health news stories followed by the American public during 1996-2002 [26], only a few studies have measured the effect of mass media on influenza vaccination [16,28-31]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Annual epidemics of seasonal influenza occur during autumn and winter in temperate regions and have imposed substantial public health and economic burdens. At the global level, these epidemics cause about 3-5 million severe cases of illness and about 0.25-0.5 million deaths each year. Although annual vaccination is the most effective way to prevent the disease and its severe outcomes, influenza vaccination coverage rates have been at suboptimal levels in many countries. For instance, the coverage rates among the elderly in 20 developed nations in 2008 ranged from 21% to 78% (median 65%). In the U.S., influenza vaccination levels among elderly population appeared to reach a "plateau" of about 70% after the late 1990s, and levels among child populations have remained at less than 50%. In addition, disparities in the coverage rates across subpopulations within a country present another important public health issue. New approaches are needed for countries striving both to improve their overall coverage rates and to eliminate disparities. This review article aims to describe a broad conceptual framework of vaccination, and to illustrate four potential determinants of influenza vaccination based on empirical analyses of U.S. nationally representative populations. These determinants include the ongoing influenza epidemic level, mass media reporting on influenza-related topics, reimbursement rate for providers to administer influenza vaccination, and vaccine supply. It additionally proposes specific policy implications, derived from these empirical analyses, to improve the influenza vaccination coverage rate and associated disparities in the U.S., which could be generalizable to other countries.
    07/2011; 44(4):141-8. DOI:10.3961/jpmph.2011.44.4.141
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite World Health Organization recommendations, the rate of 23-valent pneumococcal (PPV) and influenza (TIV) vaccination among elderly persons in Hong Kong, China, is exceptionally low because of doubts about effectiveness of vaccination. The efficacy of dual vaccination remains unknown. From 3 December 2007 to 30 June 2008, we conducted a prospective cohort study by recruiting outpatients aged ≥65 years with chronic illness to participate in a PPV and TIV vaccination program. All were observed until 31 March 2009. The outcome of subjects, including the rates of death, hospitalization, pneumonia, ischemic stroke, acute myocardial infarction, and coronary and intensive care admissions, were determined. Of the 36,636 subjects recruited, 7292 received both PPV and TIV, 2076 received TIV vaccine alone, 1875 received PPV alone, and 25,393 were unvaccinated, with a duration of follow-up of 45,834 person-years. Baseline characteristics were well matched between the groups, except that there were fewer male patients in the PPV and TIV group and fewer cases of comorbid chronic obstructive pulmonary disease among unvaccinated persons. At week 64 from commencement of the study, dual-vaccinees experienced fewer deaths (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.55-0.77]; P<.001) and fewer cases of pneumonia (HR, 0.57; 95% CI, 0.51-0.64; P<.001), ischemic stroke (HR, 0.67; 95% CI, 0.54-0.83; P<.001), and acute myocardial infarction (HR, 0.52; 95% CI, 0.38-0.71; P<.001), compared with unvaccinated subjects. Dual vaccination resulted in fewer coronary (HR, 0.59; 95% CI, 0.44-0.79; P<.001) and intensive care admissions (HR, 0.45; 95% CI, 0.22-0.94; P=.03), compared with among unvaccinated subjects. Dual vaccination with PPV and TIV is effective in protecting elderly persons with chronic illness from developing complications from respiratory, cardiovascular, and cerebrovascular diseases, thereby reducing hospitalization, coronary or intensive care admissions, and death.
    Clinical Infectious Diseases 10/2010; 51(9):1007-16. DOI:10.1086/656587 · 8.89 Impact Factor
Show more